Raphael Pharmaceutical Inc.
RAPH evidence brief
What we can confirm
- BioSniper Score:
- 2.9 / 10
- Market Cap:
- $28.2M
- Lead Asset:
- covid-19 product candidate (Preclinical)
What it means
What to watch
Prepared research question
What matters most for RAPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RAPH
Raphael Pharmaceutical Inc. (RAPH) is a clinical-stage biotechnology company developing a cannabinoid-based research platform (free of THC and CBD) for autoimmune diseases, with a preclinical pipeline and a recently launched natural formula for rheumatoid arthritis support.
Key risk: Negative equity
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$28.2M
Cash Runway
—
Lead Asset
covid-19 product candidate (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Raphael Pharmaceutical Inc..
Raphael Pharmaceutical Inc. (RAPH) is a clinical-stage biotechnology company developing a cannabinoid-based research platform (free of THC and CBD) for autoimmune diseases, with a preclinical pipeline and a recently launched natural formula for rheumatoid arthritis support.
- Raphael Pharmaceutical is developing a cannabinoid-based technology platform free of THC and CBD for autoimmune diseases [news · published 2025-11-18].
- The company has two preclinical candidates: one for hyperinflammatory syndrome related to COVID-19 and one for rheumatoid arthritis, both in collaboration with Rambam Med-Tech Ltd. [pipeline].
- In August 2025, Raphael completed development and launched RaphaWell, a natural formula for rheumatoid arthritis support in the U.S., following a proof-of-concept clinical trial [news · published 2025-08-11].
- As of 2026-06-30, the company reported net income of -$0.2M and shareholders' equity of -$1.9M [sec].
- In November 2025, Raphael filed a provisional patent application with the USPTO for its cannabinoid-based platform in treating neutrophil-dominant autoimmune diseases [news · published 2025-11-18].
What works
- Raphael has a novel cannabinoid-based platform (free of THC and CBD) that could differentiate it from other anti-inflammatory approaches [news · published 2025-11-18].
- The company has a partnership with Rambam Med-Tech Ltd. for two preclinical programs, with joint IP ownership and a royalty structure [pipeline].
- RaphaWell, a natural formula for RA support, has completed a proof-of-concept clinical trial and launched in the U.S., providing a near-term revenue opportunity [news · published 2025-08-11].
- A provisional patent application has been filed for the platform, potentially strengthening intellectual property protection [news · published 2025-11-18].
What to weigh
- Both of Raphael's drug candidates are in the preclinical phase, meaning they are years away from potential market approval [pipeline].
- The company reported negative shareholders' equity of -$1.9M as of 2026-06-30, indicating a weak financial position [sec].
- The rheumatoid arthritis space is highly competitive, with multiple large pharma companies (e.g., Eli Lilly, Novartis, Sanofi) running advanced clinical trials [competitor_trial].
- RaphaWell is a natural formula, not a pharmaceutical drug, and may face market acceptance or regulatory challenges compared to conventional DMARDs [news · published 2025-08-11].
From the filings
Quoted directly from source documents.
Raphael's platform is based on cannabinoids free of THC and CBD.
“developing an innovative research platform based on cannabinoids free of THC and CBD”
News · November 18, 2025
RaphaWell launched in the U.S. after a proof-of-concept trial.
“completed its product development and is ready to launch its proprietary natural formula under the " RaphaWell" Brand for rheumatoid arthritis ("RA") support in the United States”
News · August 11, 2025
The company has a preclinical candidate for COVID-19 hyperinflammatory syndrome.
“covid-19 product candidate Indication: Hyperinflammatory syndrome related to COVID-19 Phase: Preclinical”
Raphael filed a provisional patent application for its platform.
“announced the filing of a provisional patent application with the United States Patent and Trademark Office”
News · November 18, 2025
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$1.9M as of 2026-06-30 indicates financial distress [sec].
- Preclinical pipeline — Both drug candidates are preclinical, with no near-term regulatory milestones [pipeline].
- Intense RA competition — Multiple large pharma companies are running Phase 2/3 RA trials, creating a crowded market [competitor_trial].
- RaphaWell market risk — As a natural formula, RaphaWell may not be viewed as a direct alternative to prescription DMARDs [news · published 2025-08-11].
What to watch
- Progress of the preclinical RA and COVID-19 candidates toward clinical trials [pipeline].
- Revenue generation and market adoption of RaphaWell in the U.S. [news · published 2025-08-11].
- Outcome of the provisional patent application and any subsequent IP developments [news · published 2025-11-18].
- Financial updates, particularly any changes in cash position or equity, given the negative equity as of 2026-06-30 [sec].
Sources: Competitor trials · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Raphael Pharmaceutical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Raphael Pharmaceutical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$223K
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Raphael Pharmaceutical Inc.?
Raphael Pharmaceutical Inc. (RAPH) is a clinical-stage biotechnology company developing a cannabinoid-based research platform (free of THC and CBD) for autoimmune diseases, with a preclinical pipeline and a recently launched natural formula for rheumatoid arthritis support.
What is Raphael Pharmaceutical Inc.'s lead drug candidate?
Raphael Pharmaceutical Inc.'s most advanced tracked candidate is covid-19 product candidate (Preclinical) for Hyperinflammatory syndrome related to COVID-19.
Who is the CEO of Raphael Pharmaceutical Inc.?
Mr. Shlomo Pilo is the chief executive officer of Raphael Pharmaceutical Inc. (RAPH).
Where is Raphael Pharmaceutical Inc. headquartered?
Raphael Pharmaceutical Inc. (RAPH) is headquartered in Jaffa, Israel.
What therapeutic areas does Raphael Pharmaceutical Inc. focus on?
Raphael Pharmaceutical Inc. develops therapies across Immunology, Infectious Disease, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.